Rituximab-Vincristine Chemotherapy-Induced Acute Anterior Wall Myocardial Infarction with Cardiogenic Shock
Key result
Rituximab and vincristine linked to acute anterior MI and cardiogenic shock in a CAD patient.
- n=1
Why the study?
Chemotherapy including rituximab and vincristine can induce acute myocardial infarction with cardiogenic shock in patients with coronary artery disease, but the pathogenic mechanisms and management strategies are not well described.
Population
Elderly man with coronary artery disease and non-Hodgkin lymphoma
Comparison
Exposure to chemotherapy including rituximab and vincristine
Design
Case report
Authors
Discussion
Loading...
Member takes
Implication
May warrant vigilance for MI in CAD patients on rituximab-vincristine; single case leaves open causality and generalizability.
Study Design
Type
Case Report (n=1)
Structured PICO
P
Population
1 elderly man with coronary artery disease and non-Hodgkin lymphoma who developed acute myocardial infarction with cardiogenic shock after chemotherapy.
E
Exposure
Chemotherapy including rituximab and vincristine
O
Outcome
Acute myocardial infarction with cardiogenic shocksafety
Highlights the risk of acute myocardial infarction and cardiogenic shock following rituximab and vincristine chemotherapy in patients with underlying coronary artery disease.
Cite This Study
Roy et al. (2014) conducted a case report in Non-Hodgkin lymphoma and coronary artery disease (n=1). Rituximab and vincristine chemotherapy was evaluated on Acute myocardial infarction with cardiogenic shock. Administration of rituximab and vincristine chemotherapy in an elderly man with coronary artery disease induced acute anterior wall myocardial infarction with cardiogenic shock.